艾曲泊帕在重型再生障碍性贫血中的活性
本文综述了艾曲泊帕在重型再生障碍性贫血中的研发历程:2014年基于单药可使40%至50%患者血细胞计数恢复(常涉及>1个系)而获批用于初始免疫抑制治疗反应不足者,后续与标准马抗胸腺细胞球蛋白联合环孢素一线联合使总缓解率约90%、完全缓解率约40%。
要点
- 艾曲泊帕单药在初始免疫抑制治疗反应不足的重型再生障碍性贫血中可使40%至50%患者血细胞计数恢复。
- 艾曲泊帕联合标准马抗胸腺细胞球蛋白加环孢素一线治疗,总缓解率约90%、完全缓解率约40%。
- 所有药物同时启动时观察到最佳结果;克隆性细胞遗传学异常的累积发生率与单用免疫抑制治疗的大规模经验相比更有利。
核心结论
- 艾曲泊帕在重型再生障碍性贫血中具有单药活性,与标准马抗胸腺细胞球蛋白联合环孢素一线联合可提高总缓解率和完全缓解率,克隆性细胞遗传学异常的累积发生率与单用免疫抑制治疗的大规模经验相比更有利,更长期随访将有助于明确这些长期风险。
研究设计与样本
- 本文为综述,讨论艾曲泊帕在重型再生障碍性贫血中的研发历程。
主要发现
- 艾曲泊帕单药在初始免疫抑制治疗反应不足的重型再生障碍性贫血患者中,40%至50%血细胞计数恢复,有时涉及>1个系。
- 达到输血不依赖证实了该方法的临床获益。
- 骨髓细胞数和CD34+细胞增加提示骨髓功能恢复。
- 艾曲泊帕联合标准马抗胸腺细胞球蛋白加环孢素一线治疗,总缓解率约90%、完全缓解率约40%,并实现输血不依赖和极好生存。
- 所有药物同时启动时观察到最佳结果;克隆性细胞遗传学异常的累积发生率与单用免疫抑制治疗的大规模经验相比更有利。
关键数值与推荐
- 艾曲泊帕单药在初始免疫抑制治疗反应不足的重型再生障碍性贫血中,40%至50%患者血细胞计数恢复。
- 艾曲泊帕联合标准马抗胸腺细胞球蛋白加环孢素一线治疗,总缓解率约90%、完全缓解率约40%。
- 所有药物同时启动时观察到最佳结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 更长期随访将有助于明确克隆性细胞遗传学异常的长期风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the approval of horse antithymocyte globulin (ATG) decades ago, there was a long hiatus in therapies with activity in severe aplastic anemia (SAA). This scenario changed in 2014 when eltrombopag, a thrombopoietin receptor agonist, was approved for SAA after an insufficient response to initial immunosuppressive therapy (IST). The basis for this approval was the observation of single-agent activity of eltrombopag in this patient population, where 40% to 50% recovered blood counts at times involving >1 lineage. The achievement of transfusion independence confirmed the clinical benefit of this approach. Increase in marrow cellularity and CD34+ cells suggested a recovery to a more functioning bone marrow. Further in its development, eltrombopag was associated with standard horse ATG plus cyclosporine in first line, producing increases in overall (at about 90%) and complete response rates (at about 40%) and leading to transfusion independence and excellent survival. Interestingly, best results were observed when all drugs were started simultaneously. The cumulative incidence of clonal cytogenetic abnormalities to date has compared favorably with the vast experience with IST alone in SAA. Longer follow-up will help in define these long-term risks. In this review, the development of eltrombopag in SAA will be discussed.
引用
- Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018. PMID: 30425070. doi:10.1182/bloodadvances.2018020248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。